NCT06313593 is a Phase 1 clinical trial of INCB160058 in Myeloproliferative Neoplasms, sponsored by Incyte Corporation.

Who is sponsoring NCT06313593?

NCT06313593 is sponsored by Incyte Corporation.

What drugs are being tested in NCT06313593?

Interventions in NCT06313593: INCB160058, Standard disease-directed therapy.

What condition does NCT06313593 study?

NCT06313593 studies Myeloproliferative Neoplasms.

Is NCT06313593 still recruiting?

NCT06313593 is currently recruiting now. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT06313593

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Recruiting now Phase 1 Last updated 6 April 2026

What this trial tests

Phase 1 trial testing INCB160058 in Myeloproliferative Neoplasms in 186 participants. Currently enrolling.

Timeline

8 August 2024

Primary endpoint
9 October 2028

9 October 2028

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	186
Start date	8 August 2024
Primary completion	9 October 2028
Estimated completion	9 October 2028
Sites	31 locations across France, Italy, United Kingdom, Germany, Norway, Canada, Switzerland, United States

Drugs / interventions tested

INCB160058 — full drug profile →
Standard disease-directed therapy — full drug profile →

Conditions studied

Myeloproliferative Neoplasms — all drugs for Myeloproliferative Neoplasms →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Myeloproliferative Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel approaches in myelofibrosis.
Koschmieder S. · · 2024 · cited 7× · PMID 39670187 · DOI 10.1002/hem3.70056
Myelofibrosis: Treatment Options After Ruxolitinib Failure.
Stuckey R, Segura Díaz A, Gómez-Casares MT. · · 2025 · cited 2× · PMID 40558282 · DOI 10.3390/curroncol32060339
Investigational drugs in early phase trials for myelofibrosis.
Arora S, Vachhani P, Bose P. · · 2024 · cited 2× · PMID 39604120 · DOI 10.1080/13543784.2024.2434696
Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies.
Chen M, Zheng C, Zhang Y, He J, et al · · 2025 · PMID 41268532 · DOI 10.1155/mi/9967975

Verify or expand the search:

Other trials of INCB160058

Trials testing the same drug.

NCT06213818 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adu · Phase 1 · completed

Other recruiting trials for Myeloproliferative Neoplasms

Currently open trials in the same condition.

NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07008118 — A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT06034002 — A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye · Phase 1 · recruiting
NCT05936359 — A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye · Phase 1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06313593 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06313593.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing